We therefore hypothesised that pevonedistat will enhance the efficacy of carboplatin in combination with paclitaxel in RMC tumours by inhibiting the FANCD2‐mediated recruitment of XPF–ERCC1 to DNA ICLs induced by carboplatin. Here, FANCD2 is linked to neoplasm.